UBS analyst Ashwani Verma maintains $Neurocrine Biosciences (NBIX.US)$ with a buy rating, and adjusts the target price from $193 to $162.
According to TipRanks data, the analyst has a success rate of 49.3% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurocrine Biosciences (NBIX.US)$'s main analysts recently are as follows:
The broader U.S. Pharmaceuticals and Biotechnology sector is anticipated to face challenges outperforming in a more uncertain macroeconomic environment in the short-term. Significant legislative changes are considered likely under the incoming administration, casting a shadow of unpredictability over the sector. The uncertainty is expected to persist until more clarity is obtained regarding the governmental changes.
Q4 is expected to be generally solid for large and mid-cap commercial stage companies within the Biotech sector, aided by seasonal tailwinds. However, the outlook for 2025 might be more optimistic than justified, as several product launches may already be reflected in financial forecasts, and the sustainability of certain core franchises could pose challenges. Specifically for Neurocrine, long-term growth prospects for Ingrezza are anticipated to be driven by enhanced diagnosis and awareness of TD, although potential revenue may be limited by the Inflation Reduction Act exposure.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞士銀行分析師Ashwani Verma維持$神經分泌生物科學 (NBIX.US)$買入評級，並將目標價從193美元下調至162美元。
根據TipRanks數據顯示，該分析師近一年總勝率為49.3%，總平均回報率為5.6%。
此外，綜合報道，$神經分泌生物科學 (NBIX.US)$近期主要分析師觀點如下：
預計整個美國製藥和生物技術行業在短期內將面臨在更加不確定的宏觀經濟環境中表現優異的挑戰。人們認爲，在即將上任的政府領導下，可能會發生重大的立法變革，這給該行業蒙上了不可預測的陰影。預計不確定性將持續下去，直到政府變革得到進一步澄清。
在季節性利好風的推動下，生物技術領域的大型和中型商業舞臺公司預計第四季度將總體保持穩健。但是，2025年的前景可能比合理更樂觀，因爲一些產品的發佈可能已經反映在財務預測中，並且某些核心特許經營權的可持續性可能會構成挑戰。特別是對於Neurocrine而言，儘管潛在收入可能會受到《通貨膨脹削減法》風險敞口的限制，但預計Ingrezza的長期增長前景將受到道明診斷和認識的增強所驅動。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
